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Abstract
Background: Measurement of partial pressure of oxygen (PO2) at high temporal resolution remains a technological
challenge. This study introduces a novel PO2 sensing technology based on Multi-Frequency Phase Fluorimetry (MFPF). The
aim was to validate MFPF against polarographic Clark-type electrode (CTE) PO2 measurements.
Methodology/Principal Findings: MFPF technology was first investigated in N= 8 anaesthetised pigs at FIO2 of 0.21, 0.4, 0.6,
0.8 and 1.0. At each FIO2 level, blood samples were withdrawn and PO2 was measured in vitro with MFPF using two FOXY-
AL300 probes immediately followed by CTE measurement. Secondly, MFPF-PO2 readings were compared to CTE in an
artificial circulatory setup (human packed red blood cells, haematocrit of 30%). The impacts of temperature (20, 30, 40uC)
and blood flow (0.8, 1.6, 2.4, 3.2, 4.0 L min21) on MFPF-PO2 measurements were assessed. MFPF response time in the gas-
and blood-phase was determined. Porcine MFPF-PO2 ranged from 63 to 749 mmHg; the corresponding CTE samples from
43 to 712 mmHg. Linear regression: CTE = 15.59+1.18*MFPF (R2 = 0.93; P,0.0001). Bland Altman analysis: meandiff
69.2 mmHg, rangediff -50.1/215.6 mmHg, 1.96-SD limits -56.3/194.8 mmHg. In artificial circulatory setup, MFPF-PO2 ranged
from 20 to 567 mmHg and CTE samples from 11 to 575 mmHg. Linear regression: CTE =28.73+1.05*MFPF (R2 = 0.99;
P,0.0001). Bland-Altman analysis: meandiff 6.6 mmHg, rangediff -9.7/20.5 mmHg, 1.96-SD limits -12.7/25.8 mmHg.
Differences between MFPF and CTE-PO2 due to variations of temperature were less than 6 mmHg (range 0–140 mmHg)
and less than 35 mmHg (range 140–750 mmHg); differences due to variations in blood flow were less than 15 mmHg (all P-
values.0.05). MFPF response-time (monoexponential) was 1.4860.26 s for the gas-phase and 1.5160.20 s for the blood-
phase.
Conclusions/Significance: MFPF-derived PO2 readings were reproducible and showed excellent correlation and good
agreement with Clark-type electrode-based PO2 measurements. There was no relevant impact of temperature and blood
flow upon MFPF-PO2 measurements. The response time of the MFPF FOXY-AL300 probe was adequate for real-time sensing
in the blood phase.
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Introduction
The polarographic Clark-type electrode remains the gold
standard for oxygen partial pressure (PO2) measurement to date,
and is the underlying electrochemical principle of conventional
blood gas PO2 analysis [1,2,3,4]. Moreover, polarographic PO2
probes, such as the Licox probe, are used for the continuous
monitoring of oxygen. These probes provide favourable proper-
ties, including high accuracy and stability; however, they lack high
temporal resolution [5]. Several publications reveal that oxygen
levels may largely fluctuate over time in the systemic (e.g., thoracic
aorta) or capillary circulation (e.g. vasomotion, brain resting state)
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[6,7,8,9,10] due to oxygen consumption and delivery. Therefore,
novel, fast oxygen-sensing technologies are required for the
investigation of these physiologic or pathophysiologic phenomena
[11,12].
Recently, a novel technology for fast oxygen sensing based on
Multi Frequency Phase Fluorimetry (MFPF), termed NeoFoxH
(OceanOptics, Dunedin, USA; www.oceanoptics.com), was re-
leased. This technology is suitable for 10 Hz oxygen measurements
using fluorescent dye sensors such as the FOXY-AL300 (Ocea-
nOptics, Dunedin, USA). This indwelling, uncoated ruthenium
tipped fibre optic probe allows for rapid measurement of oxygen
within blood or tissue. The technology, however, has not yet been
compared to conventional polarographic Clark-type electrode
(CTE)-based PO2 measurements [13,14].
This study aimed to validate MFPF-PO2 measurements versus
CTE-based measurements of oxygen partial pressure. Firstly, in a
porcine lung model, MFPF-PO2 was measured in vitro without the
interference of blood flow using two FOXY-AL300 probes
(OceanOptics, Dunedin, USA) and was then compared to CTE
blood gas PO2 analysis. Secondly, for further validation, we
developed an artificial extracorporeal circulation setup primed
with a mixture of crystalloid, colloid and human packed red cells
to imitate in vivo conditions. In this setup, MFPF-PO2 readings
were assessed and then compared to conventionally measured PO2
by CTE. Furthermore, in the artificial circulation setup, temper-
ature and blood flow were randomly varied in order to evaluate
their impact on MFPF-PO2 measurements. In addition, MFPF
FOXY-AL300 (OceanOptics, Dunedin, USA) probe response
times were determined in the gas- and blood-phases to further
assess this novel technology. In summary, the overall aim could be
achieved.
Materials and Methods
MFPF Technological Principle
The MFPF platform (NeoFoxH, OceanOptics, Dundin, USA)
was mounted with the indwelling FOXY-AL300 (OceanOptics,
Dunedin, USA) aluminium-jacketed optical fibre probe (500 mm
outer and 300 mm core diameter) with an uncoated ruthenium
complex at the tip to assess luminescence lifetime in the region
surrounding the fluorescent dye, which was roughly equal to the
fibre-optic tip surface area (about 0.3 mm2). MFPF assesses
luminescence lifetime by modulation of light excitation frequency
where the oxygen dependent phase shift of the emission is
detected. Lifetime is related to phase shift by the equa-
tion:t~
tan hð Þ
2pf
, where t is calculated lifetime in s, f is LED
modulation frequency in Hz, and h is phase shift measured by the
instrument. The signals are transmitted via connected glass fibre
cable to the MFPF server (NeoFoxH, OceanOptics, Dundin, USA)
with an integrated light emitting diode, as well as temperature and
atmospheric pressure transducers. An external thermistor probe
compensates for temperature changes (once a multi-point
temperature calibration is performed). Lifetime data were logged
by NeoFoxH Software (OceanOptics, Dunedin, USA) for calcu-
lation of absolute PO2 values. Absolute PO2 values, luminescence
phase shift, luminescence intensity, temperature and ambient
pressure were displayed at a digital sampling rate of 10 Hz.
Calibration of the FOXY-AL300 Oxygen Probe
PO2 probes were calibrated at different oxygen levels and
temperatures in a closed thermostat controlled gas-tight chamber
according to the manufacturer’s instructions. The chamber was
purged with pure nitrogen (PO2= 0 mmHg), compressed air
(PO2 = 158 mmHg) and pure oxygen (PO2= 750 mmHg), respec-
tively, in consideration of atmospheric pressure with a fixed
laminar flow of 2 L min21 at 20, 30 and 40uC. After stabilisation,
the corresponding lifetimes were used to create a multi-temper-
ature calibration table.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health. The
protocol was approved by the Animal State Care and Use
Committee of the Rhineland Palatinate, Germany (Permit
Number: G07-10-013). All surgery was performed under deep
anaesthesia, and all efforts were made to minimise suffering [15].
Animal experiments were performed at the Department of
Anesthesiology, Medical Center of the Johannes Gutenberg-
University, Mainz, Germany and laboratory experiments at the
Department of Anesthesiology and Pain Therapy, Inselspital, Bern
University Hospital, and University of Bern, Switzerland.
MFPF Validation in vitro using a porcine lung model
Eight piglets, Sus scrofa domestica (2062 kg), were investigated.
After the induction of anaesthesia with a bolus of fentanyl 5 mg
kg21 i.v., propofol 2 mg kg21 i.v. and single shot atracurium
0.5 mg kg21 i.v. via an ear vein, the pigs were orotreachally
intubated (ID 8.0 mm cuffed tubing) and ventilated in pressure-
controlled mode (AVEA, Viasis Healthcare, Ho¨chberg, Germany).
Vascular access was achieved by surgical cut down for the
placement of an arterial blood pressure line in the femoral artery.
Normocapnia (PaCO2 35–45 mmHg) was maintained with a tidal
volume of 6–8 ml kg21 BW21. Anaesthesia was maintained by
continuous infusion of fentanyl (5 mg21 kg21 h21 i.v.) and propofol
(5–10 mg21 kg21 h21 i.v.). During the experiment, FIO2 was
adjusted (0.21, 0.4, 0.6, 0.8 and 1.0) to obtain PO2 readings over
the whole normobaric measurement range. Core temperature by
rectal probe was maintained within the physiologic range (37.0–
38.5uC) using a heating blanket.
Blood samples (10 ml each) were withdrawn at each FIO2 level
into heparinised gas tight syringes covered with opaque tape. For
each sample, the tips of two FOXY-AL300 probes (OceanOptics,
Dunedin, USA) were placed into the syringe outlet sealed with a
rubber port to avoid air contact. After reaching steady state values,
both MFPF-PO2 readings were simultaneously recorded for 2 min
using the corresponding animal core temperature for the
measurement. Then, the same blood sample was analysed by
conventional polarographic Clark-type electrodes (RapidLab 415,
BayerHealthcare, Leverkusen) immediately afterwards.
MFPF validation ex vivo using an artificial circulatory
setup
In order to provide standardised conditions and to simulate in
vivo conditions, an artificial circulatory system was set up. The
apparatus was built of: a) two oxygenators (Jostra Quadrox D,
Maquet Cardiopulmonary AG, Hirrlingen, Germany), b) 3/8 inch
silicon tubing (Fumedica, Muri, Switzerland) with 3/8–3/8 inch
connecting pieces (Luerlock, Fumedica, Muri, Switzerland), c) two
multi-flow roller pumps (Sto¨ckert, Munich, Germany), d) a heat
exchanger (HCU-30, Maquet Cardiopulmonary AG, Hirrlingen,
Germany) and e) an ambient light protected measurement
chamber (Figure 1). A switch valve between two independent
closed circuits enabled the induction of a step change between
highly oxygenated blood (FIO2 1.0, circuit 1) to oxygen free blood
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(FIO2 0.0, circuit 2) in order to assess the time constants of the
FOXY-AL300 probes in blood-phase.
The artificial circulatory system was primed with a mixture of
crystalloid, colloid and human packed red cells to achieve a
haematocrit of 30% and electrolyte values within the physiological
limits. This setup allowed for control and variation of blood flow
(by variation of rpm at the rollerpumps), temperature (by variation
at the membrane equilibrator) and oxygen content (by PO2
variation at the blender).
In order to get measurements over the normobaric measure-
ment range for the validation of MFPF against Clark-type
electrode PO2, FIO2 was set at random according to a computer
generated list [16] from 0.0 to 1.0. To achieve an FIO2 of less than
0.21, a mixture of oxygen and nitrogen was used. For all
measurements, duplicate MFPF PO2 readings (2 FOXY-AL300
probes) were recorded for 1 min duration alongside blood
withdrawal for conventional polarographic Clark-type electrode
PO2 analysis (ABL 700, Radiometer, Copenhagen, Denmark).
Measurements were performed according to the following
protocols:
1) To assess the agreement of MFPF vs. Clark-type electrode
PO2 at physiological body temperature conditions: at a
temperature of 37uC, blood flow of 1.6 L min21 and a sweep
gas flow of 1 L min21; 55 measurements were performed at
varying PO2 levels.
2) To assess the impact of temperature: at a blood flow of 0.5 L
min21 and sweep gas flow 0.5 L min21, temperature was set
at random according to a computer generated list [16] to 20,
30 or 40uC. For each temperature level, 15 measurements
were performed at varying PO2 levels.
3) To assess the impact of blood flow: at a temperature of 37uC
and a sweep gas flow of 2 L min21, blood flow was set at
random according to a computer generated list [16] to 0.8,
1.6, 2.4, 3.2 and 4.0 L min21. For each blood flow level, 10
measurements were performed at varying PO2 levels.
Statistical Analysis
Descriptive and statistical data analysis was performed using
SPSSH V.19 (IBM Inc., New York, USA). For metric variables,
statistical measures such as mean and standard deviation
(mean6SD) were calculated. Linear regression analysis upon
PO2 values measured by MFPF and CTE were performed. Bias
and precision values were calculated by the Bland-Altman method
[17,18]. The comparability was presented in explorative manner
by description of mean differences, range of differences and 1.96-
SD limits (lower and upper limit of agreement) [19]. In addition,
linear regression analysis of difference versus mean was performed
and then tested, if the slope is significantly different from zero.
Furthermore, intra-class correlation between the two MFPF
probes was assessed. To test the influence of blood flow and
temperature variation, a multiple linear regression model was
fitted: magnitude of PO2 measurements [(CTE+MFPF)/2], tem-
perature and blood flow as independent variables; differences of
MFPF and CTE as dependent variable. The categories of
temperature and blood flow were handled with dummy coding.
The analyses of data were done in explorative manner and the
outcome of a statistical test with a P-value,0.05 was interpreted as
statistically significant.
Results
MFPF Validation in vitro using a porcine lung model
Replicated porcine blood sampling revealed 80 duplicate
MFPF-PO2 readings (range 63 to 749 mmHg) with the corre-
sponding CTE samples (range 43 to 712 mmHg). The linear
regression was described by the equation
CTE=15.59+1.18*MFPF (R2= 0.93; P,0.0001) (Figure 2A).
Agreement by Bland Altman analysis showed a mean difference
(meandiff) in PO2 between CTE and MFPF of 69.2664.1 mmHg
(Figure 2B). The differences ranged from 250.1 to 215.6 mmHg
within the 1.96-SD limits (lower limit -56.3, upper limit
194.8 mmHg). Linear regression of the difference versus mean
showed CTE-MFPF=20.64+0.20*[(CTE+MFPF)/2] (R2 = 0.36,
slope significantly different from zero: P,0.0001). Intra-class
correlation between the two MFPF probes showed a reproduc-
ibility of R2 = 0.98.
MFPF validation ex vivo in artificial circulatory setup
In artificial circulatory setup, MFPF-PO2 measurements ranged
from 20 to 567 mmHg and the corresponding CTE samples from
11 to 575 mmHg. Linear regression yielded the equation:
CTE=28.73+1.05*MFPF (R2= 0.99; P,0.0001) (Figure 3A).
Bland-Altman analysis calculated a mean difference (meandiff)
between CTE and MFPF PO2 measurements of 6.669.8 mmHg.
Differences ranged from 29.7 to 20.5 mmHg within the 1.96-SD
limits (lower limit -12.7, upper limit 25.8 mmHg) (Figure 3B).
Linear regression of the difference versus mean showed CTE-
MFPF=28.62+0.05*[(CTE+MFPF)/2] (R2 = 0.78, slope signifi-
cantly different from zero: P,0.0001). Linear regression in a sub-
set of PO2 between 0 and 140 mmHg yielded
CTE=27.84+1.13*MFPF (R2= 0.99; P,0.0001) (Figure 4A).
Bland-Altman analysis of this sub-analysis showed a mean
difference of 1.764.9 mmHg (Figure 4B). The differences ranged
Figure 1. Artificial Circulatory Setup. Artificial circulatory setup
with two independent circuits filled with human packed red blood cells
(haematocrit of 30%). A switching valve between the circuits enabled a
step-change between highly oxygenated (circuit 1: purged with pure
oxygen) and oxygen free blood (circuit 2: purged with nitrogen). Black
arrows represent direction of blood flow. Adapting the settings of the
rollerpumps and the heating-cooling device (heat exchanger) allowed
blood-flow and temperature to be controlled. Via the O2/N2 blenders,
oxygen content could be adapted at fixed sweep gas flow over the
oxygenators. Measurement chamber contained 1.) ports for insertion of
MFPF probes (Foxy-AL 300); 2.) a temperature probe and 3.) a sampling
port for Clark-typed based (CTE) PO2 analysis (ABL 700).
doi:10.1371/journal.pone.0060591.g001
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from 27.8 to 8.1 mmHg within the 1.96-SD limits (lower limit -
8.0, upper limit 11.4 mmHg). Linear regression of the difference
versus mean yielded CTE-MFPF=27.47+0.13*[(CTE+MFPF)/
2] (R2 = 0.84, slope significantly different from zero: P,0.0001). In
total, reproducibility of R2 = 0.99 between the two MFPF probes
(intra-class correlation) was depicted.
Impact of temperature and blood flow on MFPF PO2
measurements
The influence of the temperature upon the differences of CTE
and MFPF PO2 measurements reached from 20.6 mmHg
(temperature = 20uC) to 31.8 mmHg (temperature = 40uC)
(Table 1). The influence of blood flow on difference in PO2 of
the two methods reached from 0.6 mmHg (blood flow= 1.6 L
min21) to 14.8 mmHg (blood flow= 0.8 L min21) (Table 1). The
linear regression model with the magnitude of PO2 measurements
[(CTE+MFPF)/2], temperature and blood flow as independent
variables showed a significant influence upon the magnitude of
PO2 measurements and a non-significant influence of temperature
or blood flow upon the differences of PO2 measurements
(dependent variable) (Table 2).
MFPF FOXY-AL300 Response Time
MFPF in combination with the uncoated FOXY-AL300 probes
showed a mean response time of 1.4860.26 s in gas-phase and
1.5160.20 s in blood-phase after a step-change from pure oxygen
(PO2 = 749 mmHg) to pure nitrogen (PO2= 0 mmHg) at a digital
sampling rate of 10 Hz (Figure 5). The monoexponential response
time by Boltzmann fitting represents the time it takes the system to
reach 63.2% of its final asymptotic value.
Discussion
Findings demonstrate MFPF technologys capacity for detecting
changes in PO2 compared to Clark-type electrode (CTE) based
PO2 measurements. For discrete samples, in vitro porcine blood
Figure 2. Multi Frequency Phase Fluorimetry PO2 vs. Clark-type Electrode PO2 (porcine blood in vitro, normobaric range). Panel A:
Linear regression plot, the solid line displays the line of best fit, the dashed line shows the line of identity; Panel B: Bland-Altman plot showing the
differences (CTE-MFPF) versus the means for absolute PO2 values. The dashed line represents the bias, the solid lines the 1.96 standard deviation
interval.
doi:10.1371/journal.pone.0060591.g002
Figure 3. Multi Frequency Phase Fluorimetry PO2 vs. Clark-type Electrode PO2 (human blood ex vivo, normobaric range). Panel A:
Linear regression plot, the solid line displays the line of best fit, the dashed line shows the line of identity; Panel B: Bland-Altman plot showing the
differences (CTE-MFPF) versus the means for absolute PO2 values. The dashed line represents the bias, the solid lines the 1.96 standard deviation
interval.
doi:10.1371/journal.pone.0060591.g003
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phase measurements (R2 = 0.93) did not give very tight limits of
agreement. However, this study was not designed to validate
MFPF as replacement for traditional in vitro blood gas analysis. For
such a setup, we would have needed a configuration where the
sensor and sample are part of a heated block with very tight
control of both probe and blood sample temperature. The authors
want to point out that the real application of MFPF is for flowing
blood when the probe is placed in vivo - which was investigated by
ex vivo measurements in an artificial circulatory setup filled with
human blood. These findings demonstrate that MFPF technology
provides high accuracy for PO2 measurements compared to CTE
based PO2 measurements (R
2 = 0.99). The ex vivo measurements
showed that MFPF technology accurately compensates for
variation in temperature and that PO2 measurements are not
affected by variation in blood flow. MFPF response time in
combination with the indwelling FOXY-AL300 probes was
1.4860.26 s in the gas-phase and 1.5160.20 s in the blood-phase
(step-change from pure oxygen to pure nitrogen).
In summary, MFPF technology allows for fast, accurate and
valid PO2 readings over the normobaric PO2 range (0–749 mmHg)
for ex vivo experiments, as MFPF PO2 measurements ranged
between 11 and 749 mmHg. This fact is the most important, as
novel oxygen sensing technologies should be validated over the
whole measurement range.
The in vitro animal model (porcine blood) showed good
correlation (R2 = 0.93), although the data was determined in
clusters of oxygen concentration (FIO2 0.21, 0.4, 0.6, 0.8, 1.0). The
observed high bias with positive drift as well as the enlarged
Figure 4. Multi Frequency Phase Fluorimetry PO2 vs. Clark-type Electrode PO2 (human blood ex vivo, hypoxic and normoxic range).
Panel A: Linear regression plot, the solid line displays the line of best fit, the dashed line shows the line of identity; Panel B: Bland-Altman plot
showing the differences (CTE-MFPF) versus the means for absolute PO2 values. The dashed line represents the bias, the solid lines the 1.96 standard
deviation interval.
doi:10.1371/journal.pone.0060591.g004
Table 1. Influence of temperature and blood flow on MFPF PO2 measurements.
PO2 range [mmHg] N MFPF-CTE mean MFPF-CTE SD MFPF-CTE median
Temperature [uC]
20.0 0–140 5 20.6 4.6 0.9
30.0 0–140 5 0.4 5.9 0.6
40.0 0–140 5 5.3 2.4 5.8
Total 15 1.7 5 2.9
20.0 140–600 12 13.3 28.7 28.6
30.0 140–600 11 29.4 34.9 35.9
40.0 140–600 11 31.8 21.9 40.1
Total 34 24.5 29.4 29.3
Flow [L min21]
0.80 0–600 9 14.8 4.5 17.3
1.60 0–600 7 .6 9.7 22.4
2.40 0–600 8 5.4 10.5 8.6
3.20 0–600 7 6.5 10.1 10.1
4.00 0–600 9 4.1 9.4 7.1
Total 40 6.6 9.8 8.4
PO2 = oxygen partial pressure [mmHg]; MFPF = Multi Frequency Phase Fluorimetry; CTE = Clark-type electrode; SD = standard deviation.
doi:10.1371/journal.pone.0060591.t001
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standard deviation can be most likely explained by the systemic
experimental error to use the animals’ core temperature for the in
vitro measurements. The main intention of this first series was to
obtain readings without the influence of blood flow. Therefore, we
focused on how to avoid air contact to the withdrawn blood and
decided not to insert the temperature probe into the syringes.
However, we did not expect such an impact of temperature, which
presumably seems even more evident at high PO2-levels
(Figure 2B). This finding can be explained by the underlying
MFPF technology, as in fluorescent quenching, signal intensity
increases at lower PO2 values. To fully understand the observed
discrepancy of the in vitro (porcine blood) and ex vivo (human blood)
results, we evaluated the difference of animal core temperature
and blood temperature in the syringes two minutes after
withdrawal post hoc in one further animal and found an error
range of 0.9 to 1.6uC in ten repeated measures. Nevertheless, in
the interesting physiologically hypoxic and normoxic (0–
140 mmHg) PO2 range, porcine results show that MFPF
technology provides good agreement (Figure 2B) for discrete
samples, although in our setup the technique was less accurate for
high PO2 values. Due to the underlying technological principle
precision of MFPF, PO2 values should increase within this
physiologically interesting range (0–140 mmHg), which is sup-
ported by the present data. Thus, it seems unlikely that MFPF
technology characteristics were responsible for this discrepancy, as
intra-class correlation between the MFPF probes was extremely
high (R2 = 0.99) in porcine setup and MFPF measurements in the
artificial circulatory setup (human blood) showed excellent
agreement to CTE, even at high PO2 levels. From our point of
view, the porcine results nicely demonstrate the high temperature
sensitivity of MFPF measurements and further highlight the
importance of correct temperature acquisition. Instead of repeat-
ing this series, we decided to develop a new artificial circulatory
system for further validation, where we could also investigate the
influence of temperature and blood flow by standardised variation
of these physiological values.
Under ex vivo conditions in the artificial circulatory setup
(human blood), we found excellent correlation (R2 = 0.99) of
MFPF and CTE PO2 with measurements equally distributed over
the entire normobaric range (Figure 3). In general, MFPF values
were slightly lower in comparison to CTE values. These findings
were unexpected, as the MFPF technology, unlike polarography,
does not consume any oxygen. These results might be explained
by the fact that the blood-gas-analysers used allow a potential bias
of 5% in calibration drift and it is well known that these are not
really linear over the entire range. This underestimation decreases
with lowered PO2 values and is therefore of limited clinical
importance (Figure 2, 3).
In general and as demonstrated by porcine results, temperature
is obviously one major confounder on PO2 measurement [20,21].
However, the present results of the artificial circulatory setup show
that the MFPF technology accurately compensates for alterations
in temperature if assessed strictly at the measurement site. This
fact highlights the efficiency of multi-temperature compensation
performed by MFPF software between 20 and 40uC. In this
context, it would be desirable to have sensors available with an
Table 2. Influence of temperature and blood flow on MFPF PO2 measurements: Linear regression model.
Non-standardized coefficients 95.0% CI
Independent variable Regression coefficient Standard error P-value lower limit upper limit
Temperature (base 20 6C)
Constant 22.335 10.483 0.825 223.744 19.074
PO2-magnitude [(MFPF + CTE)/2] 0.062 0.027 0.031 0.006 0.118
30uC 12.854 11.466 0.271 210.563 36.271
40uC 19.635 11.392 0.095 23.629 42.9
Blood flow (base 0.8 L min21)
Constant 24.707 2.401 0.058 29.586 0.171
PO2-magnitude [(MFPF + CTE)/2] 0.045 0.004 ,0.001 0.037 0.054
1.6 L min21 24.461 2.441 0.076 29.422 0.5
2.4 L min21 22.822 2.262 0.221 27.42 1.776
3.2 L min21 22.093 2.328 0.375 26.825 2.638
4.0 L min21 25.188 2.171 0.023 29.601 20.776
Linear regression model: magnitude of PO2 measurements, temperature and blood flow as independent variables, differences of PO2 measurements as dependent
variable. PO2 = oxygen partial pressure; MFPF = Multi Frequency Phase Fluorimetry; CTE = Clark-type electrode; CI = confidence interval.
doi:10.1371/journal.pone.0060591.t002
Figure 5. Multi Frequency Phase Fluorimetry/FOXY-AL300
Probe Response Time. Example of an MFPF step-down manoeuvre
in artificial circulatory setup (human blood-phase). The graph displays
the absolute MFPF PO2 values over the time course. The arrow marks
the time when the switching valve was changed between the
oxygenated (750 mmHg) and non-oxygenated blood (0 mmHg) circuit.
doi:10.1371/journal.pone.0060591.g005
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integrated temperature thermistor to prevent errors such as
temperature probe misplacement. In addition to temperature,
blood flow may influence PO2 measurements of an indwelling
sensor [22]. The present ex vivo results confirm that MFPF
technology correctly measures PO2, even under variations of blood
flow within the range of 0.8 to 4.0 L min21.
One major advantage of MFPF PO2 readings, next to high
agreement and reproducibility, is high temporal resolution. We
measured the monoexponential time constant for a step change in
PO2 at 1.5 s in blood. In contrast, the polagraphic Licox probe
showed response times up to several min [5,23]. Recently, faster
PO2 probes, such as the Neurovent PTO probe based on the
fluorescent quenching of oxygen, have been presented. Although
these probes reported higher response times (30 – 120 s), none of
the commercially available technologies come near the temporal
resolution of the uncoated ruthenium probe used in the current
study [23,24,25,26,27,28].
The MFPF system is easy to set up and needs no complex
calibration. In this validation study, the FOXY-AL300 probes
were individually calibrated to minimise for potential errors, but in
less demanding use, a calibration file supplied by the manufacturer
for each probe can be used with acceptable accuracy. Further-
more, phase shift is not influenced by the medium the oxygen
sensor is placed in, allowing simplified calibration in gas phase.
Moreover, phase shift measurement is not influenced by the probe
indicator dye concentration, photo bleaching of dye, or excitation
source intensity. This results in stable signals with high signal to
noise ratio [29].
Unfortunately, we could not obtain readings in a clinical setting
in patients, as the indwelling probes available up to now (e.g. the
FOXY AL-300) are not licensed for human application. There-
fore, we investigated the MFPF technology ex vivo in a self-built
artificial circulatory system filled with human blood. Although
ruthenium-based dyes are commonly used in biological monitor-
ing applications and are thought to be non-toxic, for future
application in humans, the metallic surface of the probe and its tip
containing ruthenium need to be coated with silicone or TeflonH.
In contrast to a silicone probe coating, TeflonH would allow for
more rapid diffusion of oxygen and thereby maintain ultrafast
probe response time. The challenge for the sensor engineering
community will be to avoid direct contact of the fluorescent dye to
blood components. Also, it is necessary to avoid protein absorption
and blood clotting to maintain signal stability and accuracy.
Therefore, an intensive research effort is still necessary, but if
engineering is to advance from laboratory-based research to
commercial production levels, the MFPF technique could provide
clinicians with an effective tool.
A limitation of the study is that we did not explicitly investigate
the measurement stability over time. However, the present
findings showed no calibration drift of the probes.
In summary we conclude that ex vivo MFPF-PO2 readings are
reproducible, and show excellent correlation and high agreement
with the gold standard Clark-type electrode (CTE)-based PO2
analysis. This novel technology adequately compensates for
changes in temperature and allows for accurate measurements at
various blood flow states. This feasible, accurate and easy to
calibrate method has the potential to dynamically follow changes
in blood oxygenation under various physiologic and pathophys-
iologic conditions with a high temporal resolution.
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